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MAGE-A antigens are expressed in a variety of cancers of diverse histological origin 
and germinal cells. Due to their relatively high tumor specificity, they represent attractive 
targets for active specific and adoptive cancer immunotherapies. Here, we (i) review past 
and ongoing clinical studies targeting these antigens, (ii) analyze advantages and disad-
vantages of different therapeutic approaches, and (iii) discuss possible improvements in 
MAGE-A-specific immunotherapies.
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MAGe-A tUMOr-AssOciAteD ANtiGeNs
MAGE-A were the first human tumor-associated antigens identified at the molecular level (1). 
They belong to the larger family of cancer/testis antigens (CTA), whose expression is consistently 
detected in cancers of different histological origin and germinal cells (2). The MAGE-A sub-family 
includes 12 highly homologous genes located on chromosome Xq28 (3, 4). Specific gene products 
have been identified by immunohistochemistry in cancers of different histological origin, includ-
ing high percentages of non-small cell lung cancers (NSCLC), bladder cancers, esophageal and 
head and neck cancers, and sarcomas (5). These antigens are also frequently expressed in triple 
negative breast cancers (6), myeloma (7), and Reed–Sternberg cells (8) in Hodgkin’s disease, with 
the highest frequency being detected in synovial sarcoma (9). Among healthy tissues, the expres-
sion of specific members of the family has been observed in spermatogonia, placenta (10), and 
fetal ovary (11). However, recently, MAGE-A1 and -A12 genes have been shown to be expressed 
in CNS as well, as discussed below (12).
FUNctiONAL AsPects OF MAGe-A ANtiGeNs
Preferential intracellular location may be different for different antigens, e.g., mostly cytoplasmic for 
MAGE-A1, -A3, and -A4, but mostly nuclear for MAGE-A10 (13–16).
Functions are still unclear, although different studies have associated MAGE-A2, -A3/6, and -A9 
expression with pro-tumorigenic activities such as p53 dysregulation (17–19), enhanced tumor cell 
proliferation potential, or maintenance of a cancer-stem cell-like functional profile (20).
In a variety of tumors of different histological origin, a clear correlation between expression 
of MAGE-A antigens and poor prognosis has been observed. In this context, data on bladder 
cancer (21, 22), NSCLC (23, 24), head and neck cancers (25–27), and ovarian cancer (28, 29) 
have consistently been reported. Indeed, MAGE-A antigen expression, at the gene and protein 
level, has repeatedly been shown to be associated with widespread DNA demethylation frequently 
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observed in advanced cancers. On the same line, it has been 
shown to be inducible by demethylating agents, including 
chemotherapeutic compounds widely used in cancer treatment 
such as 5-aza-2′-deoxycytidine (30, 31), thus realistically envis-
aging the possibility of treatments combining chemotherapy and 
specific vaccination (32).
iMMUNOGeNicitY OF MAGe-A 
ANtiGeNs
Although peptides restricted by both HLA classes I and II have 
been identified (33), naturally occurring adaptive immune 
responses to MAGE-A antigens are usually characterized by a 
very low frequency of specific precursors (34) in both healthy 
donors and patients bearing cancers expressing them (35). 
However, responses to MAGE-A10 have been more frequently 
detected (36, 37). Responses in tumor-associated lymphocytes 
(TIL) have seldom been explored, but we have observed that 
MAGE-A10-specific CTL could be expanded from TIL infiltrat-
ing NSCLC displaying a high expression of the target antigen 
(38). On the other hand, CTL recognizing peptide motifs 
shared by multiple MAGE-A proteins may be generated from 
peripheral blood from patients and healthy donors (39). Most 
recently, tumor reactive CD8+ T  cells, isolated based on their 
expression of activation marker (PD-1) from peripheral blood 
of melanoma patients, have been shown to relatively frequently 
target MAGE-A antigens (40).
cLiNicAL triALs tArGetiNG MAGe-A 
ANtiGeNs
In the past 10  years (2006–2016), a total of 44 clinical trials 
could be identified in “https://clinicaltrials.gov” database using 
“MAGE-A” as keyword: a total of 16 phase 0 or I, 13 phase I/
II, 13 phase II, and 2 phase III studies. Regarding immunogen 
formulations, 16 studies utilized entire proteins in the presence 
or absence of adjuvants (41, 42), 11 used peptides (43–45), 6 used 
mRNA-transfected DC (46, 47), 1 was based on tumor cell lysate-
pulsed DC, 2 took advantage of recombinant viral vectors (48, 
49), and more recently, 6 and 2 trials, respectively, have focused 
on adoptive treatments by using specific T cell receptor (TCR)-
transduced T cells (12) or expanded CTL (50).
Efficacy clinical data published so far, from patients immu-
nized in the context of the 15 larger studies (phase II or III, 
Table S1 in Supplementary Material) mainly using MAGE-A 
protein (n = 11), do not appear to support significant clinical 
effectiveness (51).
Of interest, a chronological analysis of these 44 studies clearly 
underlines a strategy shift in the most recent years. Indeed, in 
the past 4  years, among the (only) 10 clinical studies initiated 
and including MAGE-A as antigens, there are no phase II or 
III studies. Moreover, the majority of the phase I or I/II studies 
are based on adoptive cell transfer. This “shift” in MAGE-A 
translational research strategy clearly results from the combined 
effect of “protein/peptide” efficacy failure and from the confi-
dence generated by new approaches focusing on personalized 
effector T-cell treatment. In addition, one should also mention 
the shift in target paradigm from classical TAA to neo-antigens 
also contributing to the decreased use of MAGE-A antigens.
MAGe-A3 PrOteiN As iMMUNOGeN
One of the most important clinical trials ever performed in 
MAGE-A cancer immunotherapy, involving thousands of 
patients with NSCLC, was focusing on the administration of 
recombinant MAGE-A3 protein together with adjuvants (52, 
53). Despite promising initial data and the proven ability of the 
immunization protocol to induce detectable humoral responses 
in vaccinated patients (54), disease-free interval in patients with 
completely resected stage IB, II, and IIIA NSCLC did not appear 
to be significantly prolonged, as compared to patients of control 
group, in phase III studies in the context of an adjuvant therapy 
setting (41).
Why did these trials fail to reach efficacy? First, similar to 
MAGE-A antigens, a large majority of classical TAA-specific 
cancer vaccines clinically tested so far have been shown to induce 
heterogeneous immune responses rarely resulting in significant 
clinical effects.
However, specific issues should be considered for CTA-
specific immunization. For instance, MAGE-A CTA expres-
sion, a pre-requisite for the eligibility of patients for treatment 
in these studies, has usually been assessed at the gene level by 
quantitative RT-PCR (RT-qPCR) (41, 54), which cannot provide 
insights into the actual numbers of CTA-positive tumor cells. 
Immunohistochemical studies using available MAGE-A-specific 
mAbs consistently underline that expression of these antigens 
might be highly heterogeneous in cancerous tissues with high 
expression often only detectable in relatively low percentages of 
tumor cells (10, 55). Remarkably, due to the high homology of 
sequences from different components of the MAGE-A family, 
a majority of currently available reagents do recognize multiple 
antigens. Our own experience based on the use of a MAGE-A10 
highly specific mAb (Figure 1) suggests that expression of these 
antigens may be highly heterogeneous in a variety of tumors of 
different histological origin, with percentages of “positive” cells 
ranging between 5 and >60% (16). One could speculate that 
criteria based on the expression of target antigen(s), at the protein 
level, in high percentages of tumor cells and in multiple areas 
of primary and metastatic cancers could be applied for a more 
stringent selection of patients potentially eligible for MAGE-A-
targeted antitumor immunization. Additionally, it might be of 
interest to verify the expression of the target MAGE-A antigen in 
recurrent tumors following specific immunization protocols, to 
verify possible selective immune editing (56). It is worth noting, 
however, that successful antigen-specific vaccination has also 
been shown to be able to promote responsiveness against unre-
lated antigens, the so-called “antigen spreading” phenomenon 
(57), thus potentially overcoming the requirement for a uniform 
expression of target antigens in tumors to be treated.
Importantly, the recombinant protein used in most efficacy 
studies was shown to induce humoral response and HLA class 
II-restricted lymphoproliferation, as expectable (41, 53, 54). 
However, the ability of these antigen formulations to promote 
tAbLe 1 | MAGe-A gene expression, as detected by rt-qPcr in primary 
non-small cell lung cancers (NscLc) and in corresponding lymph nodes 
(LN) showing evidence of metastatic outgrowth by standard clinical 
pathology techniques.
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Tissues obtained from surgical resections from patients with NSCLC were tested 
by RT-qPCR for Mage-A1, -A2, -A3, -A4, -A10, and -A12 gene expression. 
Positivity (+) was defined by expression of at least one target gene above threshold 
(threshold = delta Ct to β-actin < 10). LN were similarly assessed by RT-qPCR and 
standard clinical pathology scoring.
FiGUre 1 | Heterogeneity of MAGe-A10 expression at the protein level. Melanoma tissues from a multi-tumor tissue microarray were stained with a 
MAGE-A10-specific reagent by standard techniques, as previously detailed (16). Antigen expression displays a high heterogeneity, regarding both percentages of 
antigen-positive tumor cells and staining intensity.
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class I-restricted responses appears to be more limited. One 
could speculate that libraries of overlapping “long” peptides (58), 
or highly immunogenic recombinant vectors (38, 59), could be 
more effective in this regard.
HeterOGeNeOUs eXPressiON OF 
MAGe-A GeNes iN PriMArY AND 
MetAstAtic cANcers
Studies from our group clearly document the heterogeneity of 
MAGE-A antigens expression at the gene expression level as well. 
We tested by RT-qPCR the expression of Mage-A1, -A2, -A3, 
-A4, -A10, and -A12 genes in primary NSCLC from 33 patients 
(Table 1). In keeping with published data (23, 24), a total of 22 
tumors (66%) showed evidence of expression of at least one of the 
antigens under investigation. Similar to recently published data in 
oral cancer (60), out of these patients with MAGE-A+ NSCLC, 10 
(45%) had lymph nodes (LN) showing evidence of tumor metas-
tasis, as compared with only 2 (18%) from the 11 MAGE-A(−) 
primary tumors. Interestingly, among the 10 metastatic LN 
from MAGE-A+ primary cancers, only half showed evidence of 
MAGE-A gene expression. Furthermore, in four LN, classified 
as non-metastatic, based on pathological evidence, expression 
of MAGE-A genes could be observed by RT-qPCR. Intriguingly, 
among LN associated with MAGE-A− primary cancers, 1/2 and 
1/8 metastatic and non-metastatic samples, respectively, showed 
evidence of MAGE-A gene expression.
Taken together, these data suggest a higher sensitivity of 
RT-qPCR as compared to standard techniques for the detec-
tion of cancer cells within LN draining primary tumor tissues. 
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Most importantly, however, they confirm the dynamic nature 
of MAGE-A antigens expression during cancer progression and 
may support the concept of combination therapies including 
treatments promoting MAGE-A antigen expression together 
with specific immunization procedures (61).
ADOPtive iMMUNOtHerAPies
In recent clinical studies, effector T cells, transduced with vectors 
encoding for specific TCRs recognizing peptides from MAGE-A3 
or MAGE-4, have been adoptively transferred into patients bear-
ing tumors expressing these antigens. Unfortunately, upon anti-
MAGE-A3, HLA-A0201-restricted TCR gene therapy, despite 
measurable clinical responses in some patients, treatment-related 
severe adverse events and deaths were also reported. These 
events may possibly be due to the high affinity of these TCRs (see 
below) and to the recognition (“on-target/off-tumor”) of highly 
homologous peptide(s) from other MAGE-A proteins expressed 
in the CNS (12, 62). Similarly, myocardial toxicity, resulting in 
treatment related death, has also been observed following gene 
therapy with a MAGE-A3-specific HLA-A0101-restricted TCR 
(63, 64). In the latter case, the “off-target” effect was attributed to 
the high homology between the target peptide and a peptide from 
Titin muscle protein.
It is worth noting that the TCR transduced into T cells in the 
first study originally derived from “humanized” mice expressing 
HLA-A0201 and its affinity toward the target antigen was further 
improved by site-directed mutagenesis (65), thus increasing the 
chances of “on-target_off-tumor” adverse events affecting tis-
sues characterized by low but detectable expression of defined 
MAGE-A antigens (12). The affinity of the TCR used in the 
second study, originally derived from a patient immunized with a 
recombinant viral vector (66), was also enhanced by site-directed 
mutagenesis.
By contrast, T cells expressing a MAGE-A4-specific TCR have 
been safely used in adoptive immunotherapy of patients with 
recurrent esophageal cancer (67).
Taken together, these data suggest that the clinical use of 
enhanced TCR effectors targeting MAGE-A antigens for cancer 
immunotherapy should be carefully evaluated in order to mini-
mize potential “off-tumor” side effects.
However, natural MAGE-A-specific TCRs, from clones 
derived from tumor bearing patients or healthy donors, might 
also be of interest. Such CTLs would probably be characterized 
by a lower affinity for cognate HLA–class I peptide complex and 
possibly by a lower antitumor effector potential, but they would 
also likely have less toxic side effects. Considering the cumulative 
potency related to the high numbers of transduced cells usually 
infused into treated patients, and their ability to proliferate and 
generate “memory,” the effectiveness of this type of treatment 
should reasonably be further tested.
cONcLUsiONs
Taken together, published data may suggest that therapeutic 
strategies targeting MAGE-A antigens have so far failed to fulfill 
the promise of representing effective tools for cancer treatment. 
However, the understanding of mechanisms controlling immune 
response as a whole and cancer-specific immune responses in 
the tumor microenvironment in particular has made enormous 
progress in the past decade, generating an unprecedented 
“momentum” for cancer immunotherapy.
Successful utilization of therapeutic mAbs recognizing 
“immunological checkpoints” is currently generating enormous 
interest in clinical oncology. Their mechanisms of actions (MoA) 
are not fully clarified (68, 69). However, one of the main MoA is 
arguably represented by the “release of brakes” hampering T cell 
responses specific for tumor-specific or associated antigens. This 
hypothesis is supported, for instance, by the higher effectiveness 
of treatment with anti CTLA-4 therapeutic mAbs in cancers 
characterized by a high mutational load, likely to result in a 
higher expression of mutated proteins potentially recognized as 
“non-self ” by the adaptive immune system (70). It is therefore 
reasonable to postulate that adequately timed combinations 
of vaccination procedures and administrations of therapeutic 
“checkpoint inhibitor” specific mAbs could be of high clinical 
relevance. Within this framework, a critical point might be 
represented by the choice of antigens of potential clinical use. 
Neo-antigens, e.g., tumor-specific mutated proteins have been 
successfully identified by whole exome sequencing (71–73), 
and the expression of defined antigenic “non-self ” peptides 
associated with restricting HLA class I determinants may be 
detected by mass spectrometry techniques (74). Although highly 
appealing, the “personal” nature of neo-antigens might possibly 
also represent their Achilles’ heel, not only because of regulatory 
hurdles (75) but also because it would likely prevent the perfor-
mance of conventional randomized trials, thereby complicating 
a reliable assessment of the effectiveness of innovative treatment 
procedures.
Based on these considerations, vaccination with tumor-asso-
ciated or CTA could still realistically find an important place in 
cancer immunotherapy in the era of “immunological checkpoint” 
inhibitors (76). Considering that MAGE-A antigens are expressed 
in tumors with poor prognosis and a scarcity of therapeutic 
options, such as TNB, and lung and esophageal cancers, it is easy 
to predict that the interest of the scientific community in CTA 
might actually be revived in the light of the enormous advances 
in cancer immunotherapy of the last years.
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